聚乙二醇-聚乳酸嵌段共聚物在药物递送系统中的应用

聚乙二醇-聚乳酸嵌段共聚物具备良好的生物相容性和生物可降解性,是良好的纳米级药物载体。嵌段共聚物具有载药能力强、粒径小、体内循环时间长、主动靶向性和被动靶向性等特点,因此在药物递送系统中得到广泛应用。简要介绍了聚乙二醇-聚乳酸嵌段共聚物的合成和性质,及其作为脂质体、胶束、微球等载体在药物递送系统中的最新进展。     

药物靶向递送策略在肿瘤免疫治疗中的应用

本文通过回顾近年来药物靶向递送策略在肿瘤免疫治疗中的有关文献,简述其优势及应用,具体分为以下三个方面进行阐述:主动性靶向递送策略、被动性靶向递送策略及内响应性和外响应性的物理化学靶向递送策略,并提出了目前的不足和未来的展望。分析表明,药物靶向递送策略在肿瘤的免疫治疗中有着广阔的应用前景,为探索更好的肿瘤免疫治疗策略提供了理论基础。     

活菌作为智能递送载体用于肿瘤治疗的研究进展

细菌经常被用作药物的载体实现被装载药物的肿瘤靶向、深部组织渗透等。近年来,通过合成生物学技术对细菌的基因进行改造,赋予了细菌环境感知和响应的功能,实现了细菌负荷药物的时空调控,促进细菌作为递送载体向更加智能化的方向发展。为此,本文综述了近年来利用细菌作为药物载体,以及基于环境感知和响应控制药物释放的细菌智能递送载体应用于癌症治疗的研究进展,最后对未来智能化的细菌载体应用于癌症治疗进行展望。     

纳米药物递送系统在前列腺癌治疗中的应用

前列腺癌（PCa）是全球最常见的男性泌尿生殖系统恶性肿瘤。手术、内分泌治疗、放疗和化疗是PCa的主要临床治疗选择。纳米药物递送系统具有良好的可控释放特性和较好的肿瘤靶向能力，并可通过增强的渗透性和保留（EPR）效应被动靶向肿瘤。通过精巧的设计组装和外表修饰赋予纳米递药系统与众不同的肿瘤治疗效果。本文介绍用于PCa治疗的先进纳米药物递送系统以及未来发展。     

纳米药物递送系统在基于化疗的联合治疗中的研究进展

肿瘤是一种病理过程复杂的疾病。大多数肿瘤患者接受化疗和放疗,但这些治疗通常只对部分有效,并产生各种严重的副作用。因此,有必要开发新的治疗策略。联合治疗是目前肿瘤治疗的热点,联合用药引起的多种协同作用是提高抗肿瘤活性的关键。纳米药物递送系统的出现对临床治疗产生了深远的影响。药物的体内递送常不能达到令人满意的治疗效果,而纳米药物递送系统可以实现肿瘤靶向给药,在提高抗肿瘤效果的同时降低药物的毒副作用。本文介绍了多种基于化疗的联合治疗方法,重点阐述了纳米药物递送系统在基于化疗的联合治疗中的运用,并对该领域面临的挑战和未来发展方向进行了展望。     

DNA折纸纳米载体在药物递送中的应用

DNA纳米技术是基于沃森克里克碱基配对原则产生可编程核酸结构的技术。因其具有高精度的工程设计、前所未有的可编程性和内在的生物相容性等特点，运用该技术合成的纳米结构不仅可以与小分子、核酸、蛋白质、病毒和癌细胞相互作用，还可以作为纳米载体，递送不同的治疗药物。DNA折纸作为一种有效的、多功能的方法来构建二维和三维可编程的纳米结构，是DNA纳米技术发展的一个里程碑。由于其高度可控的几何形状、空间寻址性、易于化学修饰，DNA折纸在许多领域具有巨大的应用潜力。本文通过介绍DNA折纸的起源、基本原理和目前进展，归纳总结了运用DNA折纸进行药物装载和释放的方式，并基于此技术，展望了今后的发展趋势以及所面临的机遇和挑战。     

透明质酸在肿瘤治疗中的应用

透明质酸(hyaluronic acid,HA)是脊椎动物细胞间基质的重要组成成分,它是一种线性生物多聚糖,具有良好的生物相容性、生物可降解、无毒、无免疫原性等特点,在生物医药领域有广泛的应用。本文简要介绍透明质酸的结构特点及其靶向作用机制,综述近年来透明质酸作为药物载体和靶向因子在肿瘤治疗中的研究现状。     

纳米递送系统线粒体靶向策略在肿瘤诊疗中的应用

肿瘤是危害人类健康的重大疾病之一。目前用于肿瘤治疗的方法有手术治疗、化学药物治疗、放射治疗等。然而,传统的治疗方法存在治疗效果不佳、易引发多药耐药、毒副作用大等缺点,仍需进一步探索新的肿瘤治疗靶点和策略。线粒体作为细胞的能量转换器,被认为是肿瘤、心血管和神经性疾病新药设计的最重要靶点之一。纳米药物递送载体具有易被主动靶向基团修饰的特点,可实现细胞乃至细胞器的精准靶向给药。本文从抑制肿瘤细胞增殖、促进肿瘤细胞凋亡、抑制肿瘤复发与转移、诱导细胞自噬等方面综述了线粒体靶向纳米载体在肿瘤诊疗中的应用。     

DNA-金属纳米材料在分子识别和药物递送中的应用

分子识别和药物递送对疾病的早期诊断和靶向治疗至关重要。DNA作为一种天然纳米分子，具有良好的生物相容性、分子识别性及序列可编程性等特点，因此在生物医学研究中受到广泛关注。然而，DNA纳米材料存在依赖于光响应系统且不能穿透细胞膜等缺点，导致单独使用无法满足实际应用的需求。近年来，涌现出大量DNA-金属纳米材料，这些复合材料具有光化学特性、组织穿透能力和药物装载能力等功能，克服了单一材料的缺陷，在生物传感、生物成像和药物靶向递送中表现出巨大的应用潜力。本文集中于3种近年热门的DNA-金属纳米材料（DNA-铜纳米材料、DNA-上转换纳米材料、DNA-金属有机框架纳米材料），依据DNA与各金属纳米材料的结合方式进行合理分类，介绍其在生物传感、生物成像和药物递送中的最新应用进展，并对未来发展方向进行了展望。     

新的药物传递系统:外泌体作为药物载体递送*

外泌体(exosomes)是细胞分泌的囊泡,在细胞与细胞之间通信中发挥重要作用。由于其固有的长距离通信能力和出色的生物相容性而具有很大的潜力作为药物递送载体,尤其适合递送蛋白质、核酸、基因治疗剂等治疗药物。许多研究表明外泌体可以有效地将许多不同种类的货物递送至靶细胞,因此,它们常被作为药物载体用于治疗。对外泌体作为药物递送系统中面临的外泌体分离,药物装载和靶向治疗应用的进展与挑战作一介绍,以期更好为外泌体药物递送系统开发提供新思路。     

新的药物传递系统:外泌体作为药物载体递送*

外泌体(exosomes)是细胞分泌的囊泡,在细胞与细胞之间通信中发挥重要作用。由于其固有的长距离通信能力和出色的生物相容性而具有很大的潜力作为药物递送载体,尤其适合递送蛋白质、核酸、基因治疗剂等治疗药物。许多研究表明外泌体可以有效地将许多不同种类的货物递送至靶细胞,因此,它们常被作为药物载体用于治疗。对外泌体作为药物递送系统中面临的外泌体分离,药物装载和靶向治疗应用的进展与挑战作一介绍,以期更好为外泌体药物递送系统开发提供新思路。     

Poly(lactic-co-glycolic acid) hollow fibre membranes for use as a tissue engineering scaffold

Mass transfer limitations of scaffolds are currently hindering the development of 3-dimensional, clinically viable, tissue engineered constructs. We have developed a poly(lactide-co-glycolide) (PLGA) hollow fibre membrane scaffold that will provide support for cell culture, allow psuedovascularisation in vitro and provide channels for angiogenesis in vivo. We produced P(DL)LGA flat sheet membranes using 1, 4-dioxane and 1-methyl-2-pyrrolidinone (NMP) as solvents and water as the nonsolvent, and hollow fibre membranes, using NMP and water, by dry/wet- and wet-spinning. The resulting fibres had an outer diameter of 700 micro m and an inner diameter of 250 micro m with 0.2-1.0 micro m pores on the culture surface. It was shown that varying the air gap and temperature when spinning changed the morphology of the fibres. The introduction of a 50 mm air gap caused a dense skin of 5 micro m thick to form, compared to a skin of 0.5 micro m thick without an air gap. Spinning at 40 degrees C produced fibres with a more open central section in the wall that contained more, larger macrovoids compared to fibres spun at 20 degrees C. Culture of the immortalised osteogenic cell line 560pZIPv.neo (pZIP) was carried out on the P(DL)LGA flat sheets in static culture and in a P(DL)LGA hollow fibre bioreactor under counter-current flow conditions. Attachment and proliferation was statistically similar to tissue culture polystyrene on the flat sheets and was also successful in the hollow fibre bioreactor. The P(DL)LGA hollow fibres are a promising scaffold to address the size limitations currently seen in tissue engineered constructs.     

Poly(lactic-co-glycolic acid) nanosphere as a vehicle for gene delivery to human cord blood-derived mesenchymal stem cells: comparison with polyethylenimine

Polyethylenimine (PEI) is one of the most extensively studied non-viral vectors but its cytotoxicity limits its clinical value. PLGA nanospheres are biocompatible and can facilitate sustained release of plasmid DNA. This study compares the cytotoxicity and long-term transgene expression between PLGA nanosphere and PEI. PLGA nanospheres were significantly less cytotoxic than PEI at various concentrations. PLGA nanospheres induced significantly higher transgene expression in vitro for a longer duration (21 days) than PEI. We conclude that PLGA nanospheres have potential as gene delivery vehicles for use in gene therapy for diseases in which a long-term therapeutic gene expression regimen is necessary.     

Layer-by-layer Assembly of Poly(lactic-co-glycolic acid)-b-poly(l-lysine) Copolymer Micelles

Biocompatible, biodegradable polyionic micelles were used as a building component for layer-by-layer (LbL) assembly that can produce drug-loaded nanolayers. To prepare the polycationic micelles, poly(lactic-co-glycolic acid)-b-poly(l-lysine) [PLGA-b-P(Lys)] copolymers were synthesized. In an aqueous phase, PLGA-b-P(Lys) copolymers were self-assembled to form spherical micelles with the inner core of poly(lactic-co-glycolic acid) (PLGA) and the cationic outer shell of P(Lys). The micelles were characterized by zeta potential, dynamic light scattering, and nuclear magnetic resonance. PLGA-b-P(Lys) micelles showed the positive zeta potential values in a broad range of pH (3–11), indicating the high stability of the polyionic micelles with the outer shell of positive charges. Cationic polymeric micelles were coated on the surface via electrostatic interactions with the oppositely charged polyelectrolyte, poly(sodium 4-styrenesulfonate). Formation of multiple micelle layers was monitored using quartz crystal microbalance in situ, and the surface topology of the layers was characterized by atomic force microscopy ex situ, as the number of micelle layer was increased. The multiple micelle layers were stable, and the thickness of micelle layer grew as the number of LbL coating increased. The approach described in this work can be used for the development of the biocompatible, biodegradable, drug-loaded bioactive nanocoatings.     

Poly(lactic-co-glycolic acid) nanospheres and microspheres for short- and long-term delivery of bioactive ciliary neurotrophic factor

Ciliary neurotrophic factor (CNTF) has been shown to be neuroprotective in the central nervous system (CNS). However, systemic administration and bolus injections have shown significant side effects and limited efficacy. Sustained, local delivery may lead to effective neuroprotection and avoid or limit adverse side effects, but sustained CNTF delivery has proven difficult to achieve and control. For controlled, sustained delivery, we investigated several processing variables in making poly(DL-lactic-co-glycolic acid) (PLGA) nano- and microspheres to optimize CNTF encapsulation and release. Nano- and microspheres were 314.9 +/- 24.9 nm and 11.69 +/- 8.16 microm in diameter, respectively. CNTF delivery from nanospheres was sustained over 14 days, and delivery from microspheres continued over more than 70 days. To assess protein bioactivity after encapsulation, neural stem cells (NSCs) were treated with CNTF released from nanospheres and compared to those treated with unencapsulated CNTF as a control. NSCs treated with CNTF expressed markers specific to mature cells, notably astrocytes; some increase in oligodendrocytic and neuronal marker expression was also observed. Significantly, cells treated with CNTF released by nanospheres exhibited a similar degree of differentiation when compared to those treated with control CNTF of equivalent concentration, showing that the process of protein encapsulation did not reduce its potency.     

药物输送系统中Janus纳米粒子的制备及应用

Janus纳米粒子(Janus nanoparticle,JNP)用于描述由两个不同侧面组合而成的一种异质结构的实体材料。Janus纳米粒子每个侧面在化学性质和/或极性上都有所差异,可将不同材料的特征和功能结合在一起,这是同类均质的材料难以实现的。近年来,Janus纳米粒子的制备方法已取得了重大突破,但其应用的发展方向仍然是一个充满挑战的领域,其中在抗肿瘤药物输送系统领域的研究较为突出。主要介绍了在药物输送系统中Janus纳米粒子的制备方法及应用,并提出了研究前景和可能面临的挑战。     

高分子囊泡在药物释放体系的应用

高分子囊泡作为一种新型的纳米药物载体,具有生物可降解性、稳定性、生物相容性及可修饰的多功能化等特点。改变聚合物种类和亲水-疏水嵌段的比例,可以制备具有不同形态和膜特性的高分子囊泡。经过修饰后的高分子囊泡,可赋予其更多的功能,从而实现药物的控释和药物靶向的能力。对高分子囊泡的结构、组成和制备方法以及在药物释放体系的应用等方面进行了较为详细的综述,目的是了解高分子囊泡最新研究进展以及未来科学家们亟须解决的重要问题。     

外泌体靶向递药在肿瘤治疗中的进展

外泌体是由细胞分泌、粒径为30～ 150 nm的纳米囊泡.外泌体具有优越的生物相容性、良好的载药功能以及便于修饰的膜表面,是一种具有潜力的药物递送载体.在肿瘤治疗研究中,可利用具有靶向识别功能的外泌体来降低脱靶效应,减少不良反应,达到增强治疗效果的目的 .归纳了用不同修饰方法增强外泌体靶向性的研究进展,总结了近五年来利...     

Orthopaedic Implant as Drug Delivery System: a Numerical Approach

Abstract

There is a current trend to propose cementless total joint arthroplasty (TJA) to younger patients. These patients have more demanding physical activity resulting in an increased failure rate of the implants. In particular for these type of patients, the desired service life of the implant should be extended. The actual implant used do not fulfil this requirement.

In this study, a new concept of orthopaedic implant is presented where the implant is not only a structural support but also a local drug delivery system. The delivered drug is meant to influence the bone remodeling in a way so as to compensate the effects of peri-implant osteolysis. To test this concept, we extended an existing bone remodeling model to include the effect of a drug. The results show that a more homogeneous bone density distribution can be obtained around the implant. Implants used as drug delivery systems could then be an alternative way to increase implant service life.